Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. (NASDAQ: GCTK) generates news primarily around its progress in implantable continuous blood glucose monitoring technology for people with diabetes and the financing activities that support this development. As a medical device and medical technology company, GlucoTrack regularly issues updates on clinical studies, advisory appointments, scientific presentations, and capital formation transactions.
Visitors to this GCTK news page can review press releases on clinical milestones, including GlucoTrack’s first-in-human study of its long-term implantable Continuous Blood Glucose Monitor (CBGM) and the initiation of a long-term, multicenter feasibility study outside the United States. The company also reports on its plans and interactions related to Investigational Device Exemption (IDE) submissions to the U.S. Food and Drug Administration, as described in its own forward-looking statements.
In addition to clinical updates, GlucoTrack publishes news about its clinical advisory team and patient engagement efforts, such as the appointment of specialists in cardiology, neuromodulation, and pain management, and the formation of a Patient Advisory Board. The company’s participation in diabetes-focused conferences and research initiatives, where it presents data on its blood-based, implantable CBGM system and epidural glucose monitoring work, is another frequent topic.
GlucoTrack’s news flow also covers financing and capital structure developments, including equity purchase agreements, private placements, and warrant repurchases described in its press releases and SEC filings. For investors and observers following GCTK, this page offers a consolidated view of GlucoTrack’s publicly disclosed corporate, clinical, and financial announcements related to its investigational CBGM platform and broader diabetes technology strategy.
Glucotrack (Nasdaq: GCTK) reported 2025 results and development progress on its fully implantable continuous blood glucose monitoring (CBGM) platform. The company received three USPTO patents, completed a $4.0 million private placement, held cash of $7.4 million at year-end, and plans an IDE filing in Q2 2026 to support a U.S. clinical trial in H2 2026.
Full‑year 2025 R&D was $9.8M, G&A $6.3M, and net loss was $19.4M versus $22.6M in 2024. An Australian multicenter feasibility study is underway.
Glucotrack (Nasdaq: GCTK) plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 to support a U.S. clinical trial for its fully implantable continuous blood glucose monitoring (CBGM) system.
Key 2025 milestones: a 10‑patient Brazil first‑in‑human study (Dec 13, 2024–Jan 31, 2025) showing MARD 7.7%, 99% data capture, no device- or procedure-related serious adverse events, an Australia feasibility study, and three US patents issued Oct–Nov 2025 (sensor chemistry, intravascular lead, low‑power electronics). US study initiation is planned for H2 2026, subject to FDA IDE approval.
Glucotrack (Nasdaq: GCTK) will present at LSI USA ’26 in Dana Point, California, March 16–20, 2026. The company presentation is scheduled for Tuesday, March 17 at 8:15 a.m. PT.
CEO Paul V. Goode, PhD, will introduce Glucotrack’s continuous blood glucose monitor (CBGM) technology, share positive first-in-human study results, and outline regulatory and U.S. commercialization plans toward a clinical trial, emphasizing a fully implantable, patient-centric device designed to reduce daily burden for people with diabetes.
Glucotrack (Nasdaq: GCTK) announced that the USPTO issued three patents for its continuous blood glucose monitoring (CBGM) platform, covering sensor chemistry, intravascular lead design, and low-power electronics.
The patents (US 12,453,494; US 12,458,257; US 12,458,258) were issued Oct 28 and Nov 4, 2025, and support the company’s multi-year implantable CBGM commercialization path designed for up to three years of continuous blood glucose measurement.
Glucotrack (Nasdaq: GCTK) entered a securities purchase agreement dated Dec 30, 2025, with a single institutional investor to sell 1,033,591 common shares (or equivalents) plus warrants to buy up to 2,067,182 shares at a combined effective price of $3.87 per share, for aggregate gross proceeds of approximately $4.0 million before fees.
The warrants carry a $3.87 exercise price, expire five years from initial exercise, and are not exercisable until shareholder approval. Closing is expected on or about Dec 31, 2025. Proceeds are planned for working capital and general corporate purposes. Curvature Securities is sole placement agent. The company agreed to file resale registration within 15 days of closing and use efforts to have it effective within 45 days.
Glucotrack (Nasdaq: GCTK) reported third-quarter 2025 results and corporate updates on November 13, 2025. The company secured new financing, increasing cash to $7.9 million as of September 30, 2025, and expects that cash to fund operations through Q1 2026. Glucotrack received $3.0 million under a Note Purchase Agreement and established an equity line of credit up to $20.0 million. Clinical progress includes initiation of a one-year, multicenter feasibility study in Australia and planned submission of an IDE to FDA in Spring 2026. Management added Dr. Usman Latif to its clinical advisory team. For nine months ended September 30, 2025, the company reported a net loss of $15.8 million compared with $12.5 million year‑ago.
Glucotrack (Nasdaq: GCTK) reconvened its Special Meeting of Shareholders for November 7, 2025 at 12:00 p.m. ET to vote on a $20 million Purchase Agreement with Sixth Borough Capital Fund LP that would permit the company, under NASDAQ Listing Rule 5635(d), to issue more than 20% of its outstanding common stock. Shareholders of record as of September 23, 2025 are entitled to vote. The Board unanimously recommends voting FOR all proposals and encourages holders to vote online, by phone, or by returning proxy cards so votes are tabulated before the meeting. Further details are available in the company’s definitive proxy filed with the SEC on October 3, 2025. Contact information for voting assistance is provided.
Glucotrack (Nasdaq: GCTK) named Usman Latif, MD, MBA to its clinical advisory team on October 29, 2025 to guide development of integrated glucose monitoring for painful diabetic neuropathy (PDN) and epidural monitoring.
Dr. Latif is an anesthesiologist and neuromodulation expert with academic appointments and clinical fellowships at institutions including Johns Hopkins, Harvard/Mass General, Yale, and University of Kansas. The company said it completed a long-term preclinical study showing feasibility and safety of epidural glucose monitoring and continues development of its implantable CBGM system with 3-year sensor longevity.
PDN affects roughly one-fifth of >38 million Americans with diabetes (~7 million people). The CBGM is an investigational device and Glucotrack highlighted regulatory, clinical trial, and financing risks.
Glucotrack (Nasdaq: GCTK) will hold a Special Meeting of Shareholders on October 31, 2025 at 12:00 p.m. ET for a shareholder vote on an Equity Purchase Agreement with Sixth Borough Capital. Shareholders of record as of September 23, 2025 are eligible to vote. The Board of Directors unanimously recommends voting "FOR" all proposals.
Shareholders are urged to vote early by telephone, online, or by returning a signed proxy card. The Company filed its definitive proxy statement with the SEC on October 3, 2025, and additional information is available at www.sec.gov. Voting assistance is available from proxy solicitors Sodali & Co. at 1-888-777-2094 or GCTK.info@investor.sodali.com.
Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes technologies, has announced its participation in the upcoming Q3 Virtual Investor Summit. Paul V. Goode, PhD, the company's President and CEO, will lead the presentation on Tuesday, September 16, 2025, at 1:30 PM ET.
The event will include a company presentation and one-on-one meetings with investors, providing an opportunity for stakeholders to learn more about Glucotrack's developments in diabetes technology.